Figure 5.
Synergistic effect of preimmunization status and ICI therapy. A, Schematic of the experiment. Half of a cohort of C57BL/6J mice were preimmunized using virus-derived peptides similar to TRP2180–188 before syngeneic B16-OVA tumor engraftment (naïve groups/PEI groups). Half of the mice in each group were subsequently treated with anti-PD1 (aPD1 groups; n = 8 each) and half with PBS (mock groups; n = 8 each). B, Average tumor volume growth shown as mean ± SEM for each treatment group. Statistical analysis by two-way ANOVA. C, Tumor volume curves of individual mice per each treatment group. The dotted line identifies the threshold of the therapeutic success rate and represents the median of the volumes measured at the endpoint for the naïve anti-PD1 group. P value is represented as follows: >0.05 (ns), ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).